ロード中...

Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis

Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....

詳細記述

保存先:
書誌詳細
出版年:Front Public Health
主要な著者: Zhang, Donger, Li, Xia, Ding, Jing, Ke, Xiatong, Ding, Wenpei, Ren, Yinan, Xu, He, Li, Hongchao, Ma, Aixia, Tang, Wenxi
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290415/
https://ncbi.nlm.nih.gov/pubmed/34295868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpubh.2021.670108
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!